Dr. Galloway is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
333 Coltman Avenue
Fox Chase Cancer Center
Philadelphia, PA 19111Phone+1 215-728-6900Fax+1 215-214-1629
Education & Training
- University of FloridaResidency, Radiation Oncology, 2006 - 2010
- MedStar Health/Georgetown University HospitalInternship, Internal Medicine, 2005 - 2006
- University of Florida College of MedicineClass of 2005
- University of FloridaB.S., Major: Chemistry; Minors: Business Administration, History, 1997 - 2001
Certifications & Licensure
- PA State Medical License 2010 - 2024
- VA State Medical License 2005 - 2006
- American Board of Radiology Radiation Oncology
Awards, Honors, & Recognition
- ARRO Educator of the Year Fox Chase Cancer Center, 2013
- Practical Radiation Oncology Certificate of Excellence in Reviewing 2013
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
- Join now to see all
Clinical Trials
- RT With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer Start of enrollment: 2010 Mar 31
- TRYHARD: Radiation Therapy Plus Cisplatin With or Without Lapatinib in Treating Patients With Head and Neck Cancer. Start of enrollment: 2013 Mar 15
- Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer Start of enrollment: 2013 Mar 22
- Join now to see all
Publications & Presentations
PubMed
- 742 citationsRadiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trialMaura L. Gillison, Andy Trotti, Jonathan Harris, Avraham Eisbruch, Paul M. Harari
Lancet. 2019-01-05 - 287 citationsNCCN Guidelines® Insights: Head and Neck Cancers, Version 1.2022.Jimmy J Caudell, Maura L Gillison, Ellie Maghami, Sharon Spencer, David G Pfister
Journal of the National Comprehensive Cancer Network. 2022-03-01 - 49 citationsThe KRAS-Variant and Cetuximab Response in Head and Neck Squamous Cell Cancer: A Secondary Analysis of a Randomized Clinical Trial.Joanne B. Weidhaas, Jonathan Harris, Dörthe Schaue, Allen M. Chen, Robert Chin
JAMA Oncology. 2017-04-01
Journal Articles
- Evaluation and management of head and neck squamous cell carcinoma of unknown primaryMartin JM, Galloway TJ, Surgical Oncology Clinics of North America, 1/1/2015
- A Phase 1 Study of CUDC-101, a multitarget inhibitor of HDACs, EGFR and HER2, in combination with chemoradiation in patients with head and neck squamous cell carcinomaGalloway TJ, Wirth L, Colevas D, Gilbert J, Bauman J, Saba N, Raben D, Mehra R, Burtness B, Jimeno A, Clinical Cancer Research, 1/1/2015
- Increasing time to treatment initiation for squamous cell carcinoma of the head and neck: An analysis of the National Cancer DatabaseMurphy CT, Galloway TJ, Handorf EA, Wang L, Mehra R, Flieder D, Ridge JA, Cancer, 1/1/2015
- Join now to see all
Books/Book Chapters
Abstracts/Posters
- One size does not fit all-Evaluating the need for separate unilateral and bilateral radiotherapy normal tissue treatment planning goals for oropharynx cancer.Wang L, Flanagan P, Gleason R, Murphy C, Churilla T, Galloway TJ, ASTRO, 1/1/2015
- PreTreatment Tumor-Specific Growth Rate as a Temporal Biomarker that Predicts Treatment Failure and Improves Risk Stratification for Oropharyngeal Cancer.Murphy CT, Devarajan K, Wang LS, Mehra R, Ridge JA, Fundakowski C, Galloway TJ, ASTRO, 1/1/2015
- Symptom Reduction from IMRT Dose Deintensification: Results from ECOG 1308 Using the Vanderbilt Head and Neck Symptom Survey Version 2 (VHNSS V2).Cmelak A, Li S, Marur S, Zhao W, Westra WH, Chung CH, Gillison ML, Gilbert J, Bauman JE, Wagner LI, Ferris RL, Trevarthen DR, Murphy BA, Galloway T, Burtness B, ASCO, 1/1/2015
- Join now to see all
Lectures
- De-intensification for favorable risk oropharynx cancer – all are created equal?University of Florida, Gainesville, FL - 1/27/2015
- Trying to make sense of an Unknown PrimaryUniversity of Florida, Gainesville, FL - 1/21/2014
- Predictive Value of p16 status on the development of a pathologic complete response (pCR) at planned neck dissection after cisplatin based chemoradiation - a second an...San Francisco, CA - 1/1/2014
- Join now to see all
Other
- Management and prevention of complications of head and neck cancer during initial treatment.Galloway TJ, Amdur RJ; Basow DS (ed), UpToDate
Waltham, MA - 1/1/2015 - Management of late complications of head and neck cancer and its treatment.Galloway TJ, Amdur RJ; Basow DS (ed), UpToDate
Waltham, MA - 1/1/2015
Press Mentions
- Head & Neck Cancer: Your Questions Answered by Fox Chase Cancer CenterApril 13th, 2022
- Many Throat Cancer Patients Can Skip Neck SurgerySeptember 17th, 2014
- Radiation for Head and Neck Cancer May Cause Problems Years LaterOctober 3rd, 2019
External Links
- Fox Chase Head and Neck Teamhttp://fccc.edu/physicians/care-team/head-neck/index.html
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: